AstraZeneca Reports P-III Trial (ADAURA) Results of Tagrisso (osimertinib) for Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer
Shots:
- The P-III trial (ADAURA) evaluating Tagrisso (80mg, qd) vs PBO in 682 patients with Stage IB, II, IIIA EGFRm NSCLC at 200+ centers across 20+ countries, incl. the US, EU, South America, Asia & the Middle East
- The results showed a clinical improvement in OS. The safety & tolerability were consistent with its established profile with no new safety concerns & the results data will be presented at an upcoming medical meeting
- Tagrisso was approved to treat early-stage lung cancer in 90+ countries, incl. in the US, EU, China, and Japan along with additional global regulatory reviews are ongoing. The company has a comprehensive portfolio of approved & potential new therapies for lung cancer
Ref: Astrazeneca | Image: Astrazenneca
Related News:- HUTCHMED and AstraZeneca Report P-II (SAVANNAH) Trial Results of Tagrisso + Savolitinib for EGFR-Mutated NSCLC
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
